

International Product List

Business Development & Licensing

2026



A focused portfolio platform for international partners

Available products, selected-market opportunities, under-development dossiers and in-process assets presented for licensing, supply and business development discussions.

Portfolio focus

● Anticoagulants

● Diabetes

● CNS

● Cardio-Renal

● MASH

● Women's Health

10

Available & selected-market assets

6

Under-development dossiers with target availability

12

In-process molecules for strategic evaluation

Market-ready portfolio

**Products available for focused partner discussions
and selected-market opportunities.**

AVAILABLE Market-ready product opportunities

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA
Apixaban	F.c. tablets	2.5 mg, 5 mg	Oral Anticoagulant
Linagliptin	F.c. tablets	5 mg	Oral Antidiabetic
Micafungin	Powder for solution for infusion	50 mg/10 ml 100 mg/10 ml	Antifungal
Rivaroxaban	F.c. tablets	2.5 mg, 10 mg 15 mg, 20 mg	Oral Anticoagulant
Sitagliptin Hydrochloride + Metformin	F.c. tablets	50 mg + 850 mg 50 mg + 1000 mg	Oral Antidiabetic
Sitagliptin Hydrochloride	F.c. tablets	25 mg, 50 mg 100 mg	Oral Antidiabetic
Sugammadex	Solution for injection	100 mg/ml	Reversion of the effect of rocuronium and vecuronium
Ticagrelor	F.c. tablets	60 mg, 90 mg	Platelet aggregation inhibitor

SELECTED MARKETS Market-ready product opportunities

Product	Form	Strength	Therapeutic area
Calcium Folate injectable	Solution for injection	200 mg / 20 ml	Detoxifying agents for antineoplastic treatment
Rosuvastatin + Ezetimibe	F.c. tablets	(5+10) mg, (10+10) mg, (20+10) mg, (40+10) mg	Treatment of high cholesterol and triglyceride levels

Under development

Pipeline products with target dossier availability for BD planning.

Development pipeline designed for practical commercial execution

Dossier availability dates are provided as planning guidance for discussions with international partners and may be further refined during project alignment.

UNDER DEVELOPMENT Dossier availability included

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA	DOSSIER
Bempedoic acid	F.c. tablets	180 mg	LDL Cholesterol	Q3 2027
Bempedoic acid + Ezetimibe	F.c. tablets	180 mg + 10 mg	LDL Cholesterol	Q3 2027
Dapagliflozin	F.c. tablets	5 mg, 10 mg	Oral Antidiabetic	Q4 2026
Dapagliflozin + Metformin	F.c. tablets	5 mg + 850 mg 5 mg + 1000 mg	Oral Antidiabetic	Q4 2026
Linagliptin + Metformin	F.c. tablets	2.5/850 mg 2.5/1000 mg	Oral Antidiabetic	Q4 2027
Safinamide Mesylate	F.c. tablets	50 mg, 100 mg	CNS / Parkinson	Q1 2027

Partner discussion points

- Territory scope and exclusivity
- Forecast and launch timing
- Regulatory pathway and dossier package
- Supply model and pricing assumptions

In process **Strategic molecules currently under evaluation for future portfolio development.**

IN PROCESS Further technical, regulatory, IP and commercial assessment required

PRODUCT	FORM	STRENGTH	THERAPEUTIC AREA
Aripiprazole tabs	F.c. tablets	TBD	CNS / Antipsychotic
Brexiprazole	F.c. tablets	0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg	CNS / Antipsychotic
Daridorexant	F.c. tablets	25 mg, 50 mg	CNS / Insomnia
Edoxaban	F.c. tablets	15 mg, 30 mg, 60 mg	Oral Anticoagulant
Ferric carboxymaltose	Solution for injection / infusion	TBD	Iron deficiency / Anemia
Fezolinetant	F.c. tablets	45 mg	Women's Health
Finerenone	F.c. tablets	10 mg, 20 mg	Cardio-Renal
Iron sucrose injection	Solution for injection / infusion	TBD	Iron deficiency / Anemia
Mavacamten	Hard capsule	2.5 mg, 5 mg, 10 mg, 15 mg	Cardiology
Resmetirom	F.c. tablets	60 mg, 80 mg, 100 mg	Hepatology / MASH
Sacubitril + Valsartan + Dapagliflozin	F.c. tablets	TBD	Cardio-Renal / Heart Failure
Vortioxetine tabs	F.c. tablets	5 mg, 10 mg, 15 mg, 20 mg	CNS / Antidepressant

Contact

Business Development & Licensing

1, A. Zaroliagki & 6, D. Lamprou Str., GR-19001 Keratea - Attica, Greece

Tel.: +30 210 341 8889 | Fax.: +30 210 866 1262

E-mail: bd@pharmazac.com | www.pharmazac.com

Licensing | Supply | Portfolio Development | International Business Development



Pharmazac
Healthcare Innovation from A to Z